ClinicalTrials.gg
RecruitingNCT07942428Updated Nov 17, 2026

Enzymatic Treatment for Postoperative Nasal Fibrosis After Rhinoplasty

An interventional study of sterile saline solution and Recombinant Lipase, Collagenase, and Hyaluronidase Preparation in Postoperative Nasal Fibrosis After Rhinoplasty, sponsored by Research Inc. Recruiting at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Research Inc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This single-arm, fixed-sequence clinical trial will evaluate an enzymatic preparation for mild-to-moderate postoperative fibrosis of the nasal soft-tissue envelope after rhinoplasty. Each participant will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed, after which the participant will receive a 3-mL enzymatic preparation in the same affected area. A second clinical assessment and ultrasound examination will be performed 2 weeks after the enzymatic treatment. Changes during the saline and enzymatic treatment periods will be compared within each participant.

Read the detailed description

Adults with mild-to-moderate fibrosis of the nasal soft-tissue envelope after rhinoplasty will receive two interventions in a fixed sequence. During Period 1, 3 mL of sterile saline will be injected into the affected nasal area. At 2 weeks, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed. The enzymatic preparation will then be injected into the same affected area. It will contain recombinant lipase, collagenase, and hyaluronidase and will be prepared by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline, for a total volume of 3 mL. Two weeks after the enzymatic treatment, clinical assessment and ultrasound, including elastography, will be repeated. All participants will receive saline first and the enzymatic preparation second.

02

Conditions studied

  • Postoperative Nasal Fibrosis After Rhinoplasty

Browse trials for

Keywords

  • Postoperative nasal fibrosis
  • rhinoplasty
  • COMPLICATION
  • Treatment
  • fibrosis
03

In context

Fibrosis

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

This study's planned enrollment of 80 is above the median of 64 across 842 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

Research Inc is the lead sponsor of 25 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older. History of rhinoplasty performed at least 3 months before enrollment. Complete healing of the surgical wounds at enrollment. Mild-to-moderate fibrosis of the nasal soft-tissue envelope in an identifiable affected area, diagnosed by clinical examination and documented by baseline high-resolution nasal ultrasonography.

Ability and willingness to provide written . Ability and willingness to complete the study assessments and follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Severe nasal fibrosis or deformity requiring surgical correction or urgent treatment.

Active infection, open wound, ulceration, or tissue necrosis in the proposed injection area.

Previous injection or other treatment specifically for nasal fibrosis Known to any component of the enzymatic preparation or to sterile saline.

Pregnancy or breastfeeding. Any medical condition that, in the investigator's judgment, makes study injections unsafe or prevents reliable completion of study assessments.

Inability to provide or comply with study procedures.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fixed Sequence: Saline Followed by Enzymatic Treatment

    All participants will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, after clinical assessment and ultrasound, they will receive 3 mL of a recombinant enzymatic preparation containing lipase, collagenase, and hyaluronidase, injected into the same affected area. The enzymatic preparation will be reconstituted with 1.5 mL of high-molecular-weight hyaluronic acid, followed approximately 5 minutes later by 1.5 mL of sterile saline. Final ultrasound and clinical assessment will be performed 2 weeks after the enzymatic treatment.

    Drug: sterile saline solution · Drug: Recombinant Lipase, Collagenase, and Hyaluronidase Preparation

Interventions

  • Drugsterile saline solution

    A total volume of 3 mL of sterile saline injected into the affected nasal area once at the beginning of the study.

  • DrugRecombinant Lipase, Collagenase, and Hyaluronidase Preparation

    A total volume of 3 mL containing recombinant lipase, collagenase, and hyaluronidase, injected into the affected nasal area 2 weeks after the saline injection. The preparation will be made by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline.

06

What researchers measure

Primary outcomes

  1. Difference in change in nasal soft-tissue thickness between the saline and enzymatic treatment periods

    High-resolution nasal ultrasonography will be used to measure soft-tissue thickness at the prespecified affected area. Measurements will be obtained before saline treatment, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. Thickness will be recorded in millimeters.

    Time frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

Secondary outcomes

  1. Difference in change in nasal soft-tissue elastography measurements between treatment

    Elastography will be recorded at the prespecified affected area at baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. The elastography parameter and units reported by the ultrasound system will be specified in the study protocol.

    Time frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

  2. Change in structural characteristics of the nasal soft-tissue envelope

    Structural characteristics of the previously operated nasal soft-tissue envelope at the affected area will be assessed by high-resolution nasal ultrasonography at each study assessment.

    Time frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

  3. Treatment-emergent adverse events

    Adverse events reported or observed after saline and enzymatic injections, including local pain, swelling, erythema, skin changes, infection, tissue injury, or other adverse events.

    Time frame: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment

07

Study locations

1 of 1 sites recruiting
  • NUARA
    Bogotá, Bogota D.C. 110121, Colombia
    Recruiting
08

References and documents

Publications

  • Nascimento NS, Torres-Obreque KM, Oliveira CA, Rabelo J, Baby AR, Long PF, Young AR, Rangel-Yagui CO. Enzymes for dermatological use. Exp Dermatol. 2024 Jan;33(1):e15008. doi: 10.1111/exd.15008. PubMed 38284197 ↗
  • Shekhter AB, Balakireva AV, Kuznetsova NV, Vukolova MN, Litvitsky PF, Zamyatnin AA Jr. Collagenolytic Enzymes and their Applications in Biomedicine. Curr Med Chem. 2019;26(3):487-505. doi: 10.2174/0929867324666171006124236. PubMed 28990520 ↗
  • Menick FJ, Salibian A. Primary intranasal lining injury cause, deformities, and treatment plan. Plast Reconstr Surg. 2014 Nov;134(5):1045-1056. doi: 10.1097/PRS.0000000000000694. PubMed 25347637 ↗
  • Kryczka J, Boncela J. Proteases Revisited: Roles and Therapeutic Implications in Fibrosis. Mediators Inflamm. 2017;2017:2570154. doi: 10.1155/2017/2570154. Epub 2017 May 31. PubMed 28642633 ↗
  • Afratis NA, Klepfish M, Karamanos NK, Sagi I. The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Adv Drug Deliv Rev. 2018 Apr;129:4-15. doi: 10.1016/j.addr.2018.03.004. Epub 2018 Apr 5. PubMed 29627371 ↗
  • Sharif-Askary B, Carlson AR, Van Noord MG, Marcus JR. Incidence of Postoperative Adverse Events after Rhinoplasty: A Systematic Review. Plast Reconstr Surg. 2020 Mar;145(3):669-684. doi: 10.1097/PRS.0000000000006561. PubMed 32097305 ↗
  • Hacker S, Pollock J, Gubisch W, Haack S. Differences between Primary and Revision Rhinoplasty: Indications, Techniques, Grafts, and Outcomes. Plast Reconstr Surg. 2021 Sep 1;148(3):532-541. doi: 10.1097/PRS.0000000000008216. PubMed 34270514 ↗

Individual participant data

Plan to share: No — non considered in the patient informed consent

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Nov 2026, 5 months.

Of 195 interventional studies with no phase under Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Jun 1, 2026
Primary completionActual
Nov 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942428
Lead sponsor
Research Inc
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jun 1, 2026
Primary completion
Nov 1, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Minyor Avellaneda, MD, Plastic surgeon
Contact
contacto@nuarabelleza.com
+57 (320) 767 4006

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion